Fibrinogen concentrate + Cryoprecipitate

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Surgical Procedures

Conditions

Cardiac Surgical Procedures, Blood Coagulation Disorders, Fibrinogen, Cryoprecipitate

Trial Timeline

Aug 1, 2010 → Nov 1, 2011

NCT ID

NCT01187225

About Fibrinogen concentrate + Cryoprecipitate

Fibrinogen concentrate + Cryoprecipitate is a phase 2 stage product being developed by CSL for Cardiac Surgical Procedures. The current trial status is completed. This product is registered under clinical trial identifier NCT01187225. Target conditions include Cardiac Surgical Procedures, Blood Coagulation Disorders, Fibrinogen.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01187225	Phase 2	Completed	Aug 1, 2010	Nov 1, 2011	Cardiac Surgical Procedures

Competing Products

20 competing products in Cardiac Surgical Procedures

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	77
regadenoson	Astellas Pharma	Pre-clinical	23
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	52
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	23
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	85
Everolimus (RAD001)	Novartis	Phase 3	77
Deferasirox and Deferoxamine	Novartis	Phase 2	52
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	85
TIN816	Novartis	Phase 2	52
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	85
Pirfenidone + Placebo	Roche	Phase 2	52
Daclizumab	Roche	Phase 1/2	41
Ranolazine + Placebo	Gilead Sciences	Phase 3	76
Insulin infusion with a goal	Novo Nordisk	Phase 3	76
Epinephrine	Pfizer	Approved	84
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	51
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	84
BMS-986224	Bristol Myers Squibb	Phase 1	32
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	51
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	32

Other Products from CSL

IgPro10Approved

four factor prothrombin complex concentrateApproved

Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP)Approved

IgPro10Approved

Blood coagulation Factor VIII and vWF, humanApproved